SARS-CoV-2 infection is associated with an increase in new diagnoses of schizophrenia spectrum and psychotic disorder: A study using the US national COVID cohort collaborative (N3C)
- PMID: 38814888
- PMCID: PMC11139284
- DOI: 10.1371/journal.pone.0295891
SARS-CoV-2 infection is associated with an increase in new diagnoses of schizophrenia spectrum and psychotic disorder: A study using the US national COVID cohort collaborative (N3C)
Abstract
Amid the ongoing global repercussions of SARS-CoV-2, it is crucial to comprehend its potential long-term psychiatric effects. Several recent studies have suggested a link between COVID-19 and subsequent mental health disorders. Our investigation joins this exploration, concentrating on Schizophrenia Spectrum and Psychotic Disorders (SSPD). Different from other studies, we took acute respiratory distress syndrome (ARDS) and COVID-19 lab-negative cohorts as control groups to accurately gauge the impact of COVID-19 on SSPD. Data from 19,344,698 patients, sourced from the N3C Data Enclave platform, were methodically filtered to create propensity matched cohorts: ARDS (n = 222,337), COVID-19 positive (n = 219,264), and COVID-19 negative (n = 213,183). We systematically analyzed the hazard rate of new-onset SSPD across three distinct time intervals: 0-21 days, 22-90 days, and beyond 90 days post-infection. COVID-19 positive patients consistently exhibited a heightened hazard ratio (HR) across all intervals [0-21 days (HR: 4.6; CI: 3.7-5.7), 22-90 days (HR: 2.9; CI: 2.3 -3.8), beyond 90 days (HR: 1.7; CI: 1.5-1.)]. These are notably higher than both ARDS and COVID-19 lab-negative patients. Validations using various tests, including the Cochran Mantel Haenszel Test, Wald Test, and Log-rank Test confirmed these associations. Intriguingly, our data indicated that younger individuals face a heightened risk of SSPD after contracting COVID-19, a trend not observed in the ARDS and COVID-19 negative groups. These results, aligned with the known neurotropism of SARS-CoV-2 and earlier studies, accentuate the need for vigilant psychiatric assessment and support in the era of Long-COVID, especially among younger populations.
Copyright: © 2024 Rahman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Update of
-
SARS-CoV-2 Infection is Associated with an Increase in New Diagnoses of Schizophrenia Spectrum and Psychotic Disorder: A Study Using the US National COVID Cohort Collaborative (N3C).medRxiv [Preprint]. 2023 Dec 5:2023.12.05.23299473. doi: 10.1101/2023.12.05.23299473. medRxiv. 2023. Update in: PLoS One. 2024 May 30;19(5):e0295891. doi: 10.1371/journal.pone.0295891. PMID: 38106125 Free PMC article. Updated. Preprint.
Similar articles
-
SARS-CoV-2 Infection is Associated with an Increase in New Diagnoses of Schizophrenia Spectrum and Psychotic Disorder: A Study Using the US National COVID Cohort Collaborative (N3C).medRxiv [Preprint]. 2023 Dec 5:2023.12.05.23299473. doi: 10.1101/2023.12.05.23299473. medRxiv. 2023. Update in: PLoS One. 2024 May 30;19(5):e0295891. doi: 10.1371/journal.pone.0295891. PMID: 38106125 Free PMC article. Updated. Preprint.
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
-
The effect of sample site and collection procedure on identification of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2024 Dec 16;12(12):CD014780. doi: 10.1002/14651858.CD014780. Cochrane Database Syst Rev. 2024. PMID: 39679851 Free PMC article.
-
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2. Cochrane Database Syst Rev. 2021. PMID: 34473343 Free PMC article.
-
Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings.Cochrane Database Syst Rev. 2022 May 6;5(5):CD015112. doi: 10.1002/14651858.CD015112.pub2. Cochrane Database Syst Rev. 2022. Update in: Cochrane Database Syst Rev. 2024 Apr 10;4:CD015112. doi: 10.1002/14651858.CD015112.pub3. PMID: 35514111 Free PMC article. Updated.
Cited by
-
Dual inflammation in schizophrenia infected with COVID-19: Impact on cognitive function.Brain Behav Immun Health. 2025 Apr 26;46:100997. doi: 10.1016/j.bbih.2025.100997. eCollection 2025 Jul. Brain Behav Immun Health. 2025. PMID: 40475701 Free PMC article.
-
Recapitulation and reversal of neuropsychiatric phenotypes in a mouse model of human endogenous retrovirus type W expression.Mol Psychiatry. 2025 Jul;30(7):3325-3337. doi: 10.1038/s41380-025-02955-9. Epub 2025 Mar 18. Mol Psychiatry. 2025. PMID: 40102613 Free PMC article.
-
Neuroimmune pathophysiology of long COVID.Psychiatry Clin Neurosci. 2025 Sep;79(9):514-530. doi: 10.1111/pcn.13855. Epub 2025 Jun 19. Psychiatry Clin Neurosci. 2025. PMID: 40536011 Free PMC article. Review.
-
Hematological and biochemical markers and cytokine levels in hospitalized psychiatric patients with COVID-19.Front Immunol. 2025 Apr 11;16:1536117. doi: 10.3389/fimmu.2025.1536117. eCollection 2025. Front Immunol. 2025. PMID: 40292283 Free PMC article.
-
Neurobiology of COVID-19-Associated Psychosis/Schizophrenia: Implication of Epidermal Growth Factor Receptor Signaling.Neuropsychopharmacol Rep. 2025 Mar;45(1):e12520. doi: 10.1002/npr2.12520. Neuropsychopharmacol Rep. 2025. PMID: 39754403 Free PMC article. Review.
References
-
- Taquet M., Geddes J., Husain M., Luciano S. & Harrison P. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry. 8, pp. 416–427 (2021). doi: 10.1016/S2215-0366(21)00084-5 - DOI - PMC - PubMed
MeSH terms
Grants and funding
- U54 GM104938/GM/NIGMS NIH HHS/United States
- UL1 TR002649/TR/NCATS NIH HHS/United States
- UL1 TR002548/TR/NCATS NIH HHS/United States
- UL1 TR001433/TR/NCATS NIH HHS/United States
- UL1 TR001422/TR/NCATS NIH HHS/United States
- UL1 TR001860/TR/NCATS NIH HHS/United States
- UL1 TR001427/TR/NCATS NIH HHS/United States
- U54 GM104942/GM/NIGMS NIH HHS/United States
- UL1 TR001420/TR/NCATS NIH HHS/United States
- UL1 TR001439/TR/NCATS NIH HHS/United States
- UL1 TR002243/TR/NCATS NIH HHS/United States
- UL1 TR001445/TR/NCATS NIH HHS/United States
- UL1 TR003096/TR/NCATS NIH HHS/United States
- UL1 TR002537/TR/NCATS NIH HHS/United States
- UL1 TR001857/TR/NCATS NIH HHS/United States
- UL1 TR001412/TR/NCATS NIH HHS/United States
- U54 GM133807/GM/NIGMS NIH HHS/United States
- UL1 TR001872/TR/NCATS NIH HHS/United States
- UL1 TR001878/TR/NCATS NIH HHS/United States
- UL1 TR002529/TR/NCATS NIH HHS/United States
- UL1 TR001863/TR/NCATS NIH HHS/United States
- UL1 TR002494/TR/NCATS NIH HHS/United States
- UL1 TR002736/TR/NCATS NIH HHS/United States
- U54 GM115516/GM/NIGMS NIH HHS/United States
- UL1 TR002369/TR/NCATS NIH HHS/United States
- UL1 TR002541/TR/NCATS NIH HHS/United States
- U54 GM115371/GM/NIGMS NIH HHS/United States
- UL1 TR002001/TR/NCATS NIH HHS/United States
- UL1 TR002538/TR/NCATS NIH HHS/United States
- U54 GM115458/GM/NIGMS NIH HHS/United States
- UL1 TR001442/TR/NCATS NIH HHS/United States
- UL1 TR002535/TR/NCATS NIH HHS/United States
- UL1 TR001866/TR/NCATS NIH HHS/United States
- UL1 TR003167/TR/NCATS NIH HHS/United States
- UL1 TR001409/TR/NCATS NIH HHS/United States
- UL1 TR001449/TR/NCATS NIH HHS/United States
- UL1 TR001453/TR/NCATS NIH HHS/United States
- UL1 TR002489/TR/NCATS NIH HHS/United States
- U54 GM104940/GM/NIGMS NIH HHS/United States
- UL1 TR003107/TR/NCATS NIH HHS/United States
- UL1 TR003015/TR/NCATS NIH HHS/United States
- UL1 TR002733/TR/NCATS NIH HHS/United States
- U24 TR002306/TR/NCATS NIH HHS/United States
- UL1 TR002003/TR/NCATS NIH HHS/United States
- UL1 TR001876/TR/NCATS NIH HHS/United States
- UL1 TR001436/TR/NCATS NIH HHS/United States
- UL1 TR002378/TR/NCATS NIH HHS/United States
- UL1 TR002384/TR/NCATS NIH HHS/United States
- UL1 TR002553/TR/NCATS NIH HHS/United States
- UL1 TR002389/TR/NCATS NIH HHS/United States
- UL1 TR001414/TR/NCATS NIH HHS/United States
- U54 GM104941/GM/NIGMS NIH HHS/United States
- UL1 TR002014/TR/NCATS NIH HHS/United States
- UL1 TR002550/TR/NCATS NIH HHS/United States
- UL1 TR002319/TR/NCATS NIH HHS/United States
- UL1 TR001855/TR/NCATS NIH HHS/United States
- UL1 TR001425/TR/NCATS NIH HHS/United States
- UL1 TR002373/TR/NCATS NIH HHS/United States
- UL1 TR002240/TR/NCATS NIH HHS/United States
- UL1 TR002556/TR/NCATS NIH HHS/United States
- UL1 TR003017/TR/NCATS NIH HHS/United States
- UL1 TR001998/TR/NCATS NIH HHS/United States
- UL1 TR001873/TR/NCATS NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- UL1 TR002645/TR/NCATS NIH HHS/United States
- UL1 TR001450/TR/NCATS NIH HHS/United States
- UL1 TR002366/TR/NCATS NIH HHS/United States
- U54 GM115428/GM/NIGMS NIH HHS/United States
- UL1 TR002345/TR/NCATS NIH HHS/United States
- UL1 TR002377/TR/NCATS NIH HHS/United States
- U54 GM115677/GM/NIGMS NIH HHS/United States
- UL1 TR002544/TR/NCATS NIH HHS/United States
- UL1 TR003098/TR/NCATS NIH HHS/United States
- UL1 TR001430/TR/NCATS NIH HHS/United States
- UL1 TR003142/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous